Affiliation |
Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Urology |
Title |
Associate Professor |
External Link |
MUKAI Shoichiro
|
|
Papers 【 display / non-display 】
-
Dysregulation of type II transmembrane serine proteases and ligand-dependent activation of MET in urological cancers Invited Reviewed
Mukai S., Yamasaki K., Fujii M., Nagai T., Terada N., Kataoka H., Kamoto T.
International Journal of Molecular Sciences 21 ( 8 ) 2020.4
Authorship:Lead author, Corresponding author Language:English Publishing type:Research paper (scientific journal) Publisher:International Journal of Molecular Sciences
Unlike in normal epithelium, dysregulated overactivation of various proteases have been reported in cancers. Degradation of pericancerous extracellular matrix leading to cancer cell invasion by matrix metalloproteases is well known evidence. On the other hand, several cell-surface proteases, including type II transmembrane serine proteases (TTSPs), also induce progression through activation of growth factors, protease activating receptors and other proteases. Hepatocyte growth factor (HGF) known as a multifunctional growth factor that upregulates cancer cell motility, invasiveness, proliferative, and anti-apoptotic activities through phosphorylation of MET (a specific receptor of HGF). HGF secreted as inactive zymogen (pro-HGF) from cancer associated stromal fibroblasts, and the proteolytic activation by several TTSPs including matriptase and hepsin is required. The activation is strictly regulated by HGF activator inhibitors (HAIs) in physiological condition. However, downregulation is frequently observed in cancers. Indeed, overactivation of MET by upregulation of matriptase and hepsin accompanied by the downregulation of HAIs in urological cancers (prostate cancer, renal cell carcinoma, and bladder cancer) are also reported, a phenomenon observed in cancer cells with malignant phenotype, and correlated with poor prognosis. In this review, we summarized current reports focusing on TTSPs, HAIs, and MET signaling axis in urological cancers.
DOI: 10.3390/ijms21082663
-
Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis. Reviewed
Mukai S, Sakamoto N, Kakinoki H, Shibuya T, Moriya R, Nishihara K, Noguchi M, Shin T, Fujimoto N, Igawa T, Ishii T, Haga N, Enokida H, Eto M, Kamba T, Sakai H, Saito S, Terada N, Kamoto T
Journal of clinical medicine 11 ( 12 ) 2022.6
Authorship:Lead author, Corresponding author Language:English Publishing type:Research paper (scientific journal)
DOI: 10.3390/jcm11123538
-
Possible role of combined therapy targeting MET and pro-HGF activation for renal cell carcinoma: analysis by human HGF-producing SCID mice. Reviewed
Fujii M, Akioka T, Kimura S, Nagai T, Kiwaki T, Fukushima T, Mukai S, Kamoto T
Human cell 36 ( 2 ) 775 - 785 2023.3
Authorship:Corresponding author Language:English Publishing type:Research paper (scientific journal)
-
Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu–Okinawa area of Japan Reviewed
Nakanishi S., Fukushima Y., Inokuchi J., Hakariya T., Kakinoki H., Enokida H., Chikui K., Matsuoka H., Shin T., Mukai S., Kamba T., Eto M., Imamura R., Noguchi M., Igawa T., Haga N., Kamoto T., Fujimoto N., Saito S.
International Journal of Urology 2024
Language:English Publishing type:Research paper (scientific journal) Publisher:International Journal of Urology
Objective: Adrenocortical carcinoma is a rare condition, with limited comprehensive reports from Japan. This study aimed to review Japan's data on adrenocortical carcinoma by assessing information from 46 patients—with adrenocortical carcinoma across 10 Japanese university hospitals. Methods: We conducted a retrospective multi-institutional analysis of the clinical characteristics of adrenocortical carcinoma in Japan. We evaluated data from 46 patients across 10 university hospitals over 10 years and analyzed the relationship between clinicopathological characteristics and overall survival. Results: Five- and 10-year overall survival rates were 59% and 53%, respectively. Overall survival was significantly different among the tumor–node–metastasis system for adrenocortical carcinoma of the American Joint Committee on Cancer/International Union Against Cancer, with the worst prognosis in stage IV (p = 0.0044). In our cohort, neither the Weiss score nor the Ki-67 proliferation index correlated with overall survival. Adjuvant treatment did not yield improved overall survival, whereas resection of the primary tumor in stage IV disease was significantly associated with improved overall survival (p = 0.0262). Out of the cases evaluated for plasma hormones, plasma cortisol, aldosterone, testosterone, and DHEA-S levels were measured at 23%, 42%, 29%, and 62%, respectively, demonstrating higher levels than the upper normal limits. Conclusion: Patients with stage IV adrenocortical carcinoma had a poor prognosis; however, resection of the primary tumor in stage IV disease was associated with prolonged survival. The results of this study are expected to contribute to future treatment of adrenocortical carcinoma in Japan.
DOI: 10.1111/iju.15386
-
Miyamoto Y., Kawasoe C., Ito K., Oguri N., Murashima T., Kamibeppu T., Nagai T., Takamori H., Kamimura T., Mukai S., Sato Y., Kamoto T.
Journal of Medical Case Reports 17 ( 1 ) 2023.12
Authorship:Corresponding author Language:English Publishing type:Research paper (scientific journal) Publisher:Journal of Medical Case Reports
Introduction: Methotrexate induces lymphoproliferative disorders on rare occasions; however, its pathogenesis remains unknown. A clinical diagnosis based on imaging studies alone is often difficult. Case presentation: A 57-year-old Japanese woman was referred to our department for the evaluation of multiple lung and hepatic nodules that developed during methotrexate treatment for rheumatoid arthritis. Since she had a history of nephrectomy for localized renal cell carcinoma, multiple lung and hepatic metastases were initially considered. However, pathological diagnosis of the lung nodules (needle biopsy) revealed methotrexate-associated polymorphic-type lymphoproliferative disorders. After methotrexate discontinuation, continuous smooth shrinkage of the lung and liver lymphoproliferative disorders was observed. Conclusion: Methotrexate-associated lymphoproliferative disorders should be considered in the event of newly appearing neoplastic lesions, even during follow-up for renal cell carcinoma, if methotrexate is being administered.
Books 【 display / non-display 】
-
術式の選択基準と周術期アセスメント1.副腎腫瘍 泌尿器Care & Cure Uro-Lo
向井尚一郎( Role: Sole author)
メディカ出版 2019
Language:Japanese
-
Urologic Surgery Next1腹腔鏡手術 Ⅳ前立腺・膀胱の手術「腹腔鏡下前立腺全摘除術」
向井尚一郎,髙森大樹,賀本敏行( Role: Joint author)
メジカルビュー社 2018
Language:Japanese Book type:Textbook, survey, introduction
-
Urologic Surgery Next1腹腔鏡手術 Ⅳ前立腺・膀胱の手術「腹腔鏡下前立腺全摘除術」
向井尚一郎,髙森大樹,賀本敏行( Role: Joint author)
メジカルビュー社 2018
Language:Japanese Book type:Textbook, survey, introduction
-
精巣癌の治療 3. (2) 救済化学療法 日本臨床
向井尚一郎( Role: Sole author)
日本臨床社 2017
Language:Japanese
-
精巣癌の治療 3. (2) 救済化学療法 日本臨床
向井尚一郎( Role: Sole author)
日本臨床社 2017
Language:Japanese
MISC 【 display / non-display 】
-
前立腺がんの放射線療法(外照射、内照射)ってどんな治療法?
向井尚一郎
泌尿器care&cure Uro-Lo 21 ( 1 ) 41 - 44 2016.1
Language:Japanese Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher:メディカ出版
-
がん微小環境におけるtype Ⅱ transmembrane serine protease (TTSP) の働きについて (肝細胞増殖因子の活性化酵素とその制御機構を中心に)
向井尚一郎、月野浩昌
西日本泌尿器科 77 ( 10 ) 365 - 373 2015.10
Language:Japanese Publishing type:Article, review, commentary, editorial, etc. (scientific journal) Publisher:西日本泌尿器科
-
Laparoscopic anterior pelvic exenteration for locoregionally advanced rectal cancer directly invading the urinary bladder: A case report of low anterior resection with en bloc cystectomy for sphincter preservation.
石崎秀信、向井尚一郎他
Asian J Endosc Surg 2015.8
Language:English Publishing type:Article, review, commentary, editorial, etc. (scientific journal) Publisher:Wiley Online Library
-
RCCにおける分子標的治療の総括
向井尚一郎、賀本敏行
西日本泌尿器科 77 ( 4 ) 115 - 123 2015.4
Language:Japanese Publishing type:Article, review, commentary, editorial, etc. (scientific journal) Publisher:西日本泌尿器科
-
下大静脈塞栓を伴う腎細胞癌に対する手術戦略(症例検討会)
北悠希、向井尚一郎、賀本敏行
宮崎県医師会医学雑誌 38 ( 1 ) 49 - 52 2014.4
Language:Japanese Publishing type:Article, review, commentary, editorial, etc. (other) Publisher:宮崎県医師会
Presentations 【 display / non-display 】
-
大きな褐色細胞腫, 後腹膜腫瘍へのアプローチ~腹腔鏡の利用について
向井尚一郎
第32回日本泌尿器内視鏡学会総会
Event date: 2018.11.27 - 2018.11.29
Language:Japanese Presentation type:Symposium, workshop panel (nominated)
-
ロボット時代の若手教育 標準術式の習得について
向井尚一郎
第106回日本泌尿器科学会総会
Event date: 2018.4.19 - 2018.4.22
Language:Japanese Presentation type:Public lecture, seminar, tutorial, course, or other speech
-
骨盤内蔵全摘における泌尿器科の関わりについて
向井尚一郎,武田将司,賀本敏行,西田卓弘,河野文彰,池田拓人,七島篤志,石崎秀信,魏峻洸
第30回日本内視鏡外科学会総会
Event date: 2017.12.7 - 2017.12.9
Language:Japanese Presentation type:Symposium, workshop panel (nominated)
-
超高齢時代のCRPC患者に対する骨マネジメントについて
向井尚一郎,藤井将人,月野浩昌,賀本敏行
第69回西日本泌尿器科学会
Event date: 2017.11.9 - 2017.11.12
Language:Japanese Presentation type:Symposium, workshop panel (nominated)
-
HAI-2 regulates the growth of RCC cells in bone metastasis through suppression of matripatese International conference
Mukai S
The 34th Korea –Japan Urological Congress
Event date: 2017.10.23
Language:Japanese
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
転移性CRPCにおける、HGF/METパスウェイを標的とした新規治療法の開発
Grant number:23K08737 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
Authorship:Coinvestigator(s)
-
ヒト化マウスを用いた腎細胞癌PDXモデルの樹立とMET阻害薬効果予測因子の同定
Grant number:22K09506 2022.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
Authorship:Principal investigator
-
腎癌骨転移における膜結合型タンパクの機能解析と新規治療法の確立
Grant number:15K10598 2015.04 - 2018.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
Authorship:Principal investigator
腎癌骨転移における膜結合型タンパクの機能解析と新規治療法の確立